Research programme: antibacterials - Karo BioAlternative Names: Antibacterial research programme - Karo Bio
Latest Information Update: 19 Sep 2006
At a glance
- Originator Karo Bio USA
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 09 Jul 2001 Preclinical development for Bacterial infections in USA (Unknown route)